期刊文献+

突变型p53蛋白稳定表达机制的研究进展 被引量:1

Research progress in stabilization mechanism of mutant p53 protein expression
原文传递
导出
摘要 野生型p53(wild-type p53,wtp53)是一种抑癌基因,细胞内其蛋白的稳定性受鼠双微体2(mouse double minute 2,MDM2)蛋白的调节,保持在一个较低的水平;但是p53基因突变后其功能即发生改变,从抑癌基因转变成了对肿瘤发生和发展起促进作用的癌基因,且在肿瘤中高表达。因此,突变型p53(mutant type p53,mtp53)已经成为肿瘤治疗中一个重要的靶点。研究显示,mtp53蛋白的稳定性对其表达并行使功能具有重要作用。因此,了解mtp53蛋白稳定表达的途径,即可为下调mtp53的表达提供一些新的靶点,为肿瘤治疗提供新的途径。本研究旨在对影响mtp53蛋白稳定性的可能途径作一综述。 Wild type p53 (wtp53) is a tumor suppressor gene, and the stability of p53 protein expression in cells is regulated by mouse double minute 2 (MDM2) protein and keeps at a low level. However, when the p53 gene is mutant, it can gain the function to promote the generation and progression of tumors and is highly expressed in tumor cells. Therefore, mutant p53 (mtp53) has become an attractive target for cancer therapy. The stability of mutant p53 protein has an important role in its functions. Hence, the understanding of the way of mtp53’s stable expression can provide not only a new target for the degradation of mtp53 protein expression, but also a new strategy for cancer therapy. This review summarizes the research progress in stabilization mechanism of mtp53 protein expression.
出处 《肿瘤》 CAS CSCD 北大核心 2014年第7期673-677,共5页 Tumor
基金 国家自然科学基金云南联合基金资助项目(编号:U1132604) 国家自然科学基金资助项目(编号:81260501)
关键词 肿瘤 基因 p53 HSP90热休克蛋白质类 自噬 组蛋白脱乙酰基酶类 Neoplasms Genes, p53 Heat-shock protein 90 Autophagy Histone deacetylases
  • 相关文献

参考文献1

二级参考文献3

共引文献7

同被引文献23

  • 1Chen L,She X,Wang T, et al.Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles[J].Nanoscale,2015,7(33):14080-14092.
  • 2de Anta JM,Perez-Castro Ai,Freire R,et al.The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance[J].Anticancer Drugs,2006,17(10):1171-1177.
  • 3Huang L,Hu C,Di Benedetto M,et al. Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib[J].Onco Targets Ther,2015,7:2249-2255.
  • 4Walsh N, Larkin A, Kennedy S, et al.Expression of multidrug resistance markers ABCBl(MDR-1/P-gp)and ABCCI(MRP-1)in renal cell carcinoma[J].BMC Urol,2009,9:6.
  • 5Austrup J,Ntais P, Christodoulou V,et al.Erratum to:Frequency of MDR I -related p-gp overexpression in Creek Leishmania isolates[J].Parasitol Res,2015,114(9):3565.
  • 6Baumert C,Cunthel M,Krawczyk S, et al.Development of small-molecule P-gp inhibitors of the N-benzyl 1,4-dihydropyridine type:novel aspects in SAR and bioanalytical evaluation of multidrug resistance(MDR)reversal properties[J].Bioorg Med Chem,2012,21(1):166-177.
  • 7Colabufo NA,Contino M,Berardi F,et al.A new generation of MDR modulating agents with dual activity:P-gp inhibitor and iNOS Inducer agents[J]. Toxicol In Vitro,2010,25(1):222-230.
  • 8Ara N,Atique M,Ahmed S,et al.Frequency of p53 gene mutation and protein expression in oral squamous cell carcinoma[J]. J Coll Physicians Surg Pak12014,24(10):749-753.
  • 9Li Z, Sun Y, Chen X,et al.p53 mutation directs aurka overexpression via miR-25 and FBXW7 in prostatic smalt cell neuroendocrine carcinoma[J].Mol Cancer Res,2014,13(3):584-591.
  • 10Qi LN,Bai T,Chen ZS,ef al.The p53 mutation spectrum in hepatocellular carcinoma from Guangxi,China:role of chronic hepatitis B virus infection and aflatoxin BI exposure[J]. Liver lnt,2014,35(3):999-1009.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部